Literature DB >> 22525828

IBD: Mucosal healing--EXTENDing our knowledge in Crohn's disease.

Silvio Danese, Laurent Peyrin-Biroulet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22525828     DOI： 10.1038/nrgastro.2012.77

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease.

Authors:  Laurent Peyrin-Biroulet; Marc Ferrante; Fernando Magro; Simon Campbell; Denis Franchimont; Herma Fidder; Hans Strid; Sandro Ardizzone; Gigi Veereman-Wauters; Jean-Baptiste Chevaux; Mathieu Allez; Silvio Danese; Andreas Sturm
Journal:  J Crohns Colitis       Date:  2011-08-03       Impact factor: 9.071

Review 2.  MRI in Crohn's disease--current and future clinical applications.

Authors:  Gionata Fiorino; Cristiana Bonifacio; Alberto Malesci; Luca Balzarini; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-22       Impact factor: 46.802

Review 3.  Clinical implications of mucosal healing for the management of IBD.

Authors:  Guillaume Pineton de Chambrun; Laurent Peyrin-Biroulet; Marc Lémann; Jean-Frédéric Colombel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-12-01       Impact factor: 46.802

4.  Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.

Authors:  Laurent Peyrin-Biroulet; Vincent Billioud; Geert D'Haens; Remo Panaccione; Brian Feagan; Julian Panés; Silvio Danese; Stefan Schreiber; Haruhiko Ogata; Toshifumi Hibi; Peter D R Higgins; Laurent Beaugerie; Yehuda Chowers; Edouard Louis; Flávio Steinwurz; Walter Reinisch; Paul Rutgeerts; Jean-Frédéric Colombel; Simon Travis; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2012-12       Impact factor: 10.864

5.  Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.

Authors:  Geert D'Haens; Marc Ferrante; Severine Vermeire; Filip Baert; Maja Noman; Liesbeth Moortgat; Patricia Geens; Doreen Iwens; Isolde Aerden; Gert Van Assche; Gust Van Olmen; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2012-02-16       Impact factor: 5.325

6.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

Review 7.  Adalimumab in Crohn's disease: tips and tricks after 5 years of clinical experience.

Authors:  G Fiorino; H Szabò; W Fries; A Malesci; L Peyrin-Biroulet; S Danese
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

8.  Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.

Authors:  Paul Rutgeerts; Gert Van Assche; William J Sandborn; Douglas C Wolf; Karel Geboes; Jean-Frédéric Colombel; Walter Reinisch; Ashish Kumar; Andreas Lazar; Anne Camez; Kathleen G Lomax; Paul F Pollack; Geert D'Haens
Journal:  Gastroenterology       Date:  2012-02-08       Impact factor: 22.682

9.  Development of the Crohn's disease digestive damage score, the Lémann score.

Authors:  Benjamin Pariente; Jacques Cosnes; Silvio Danese; William J Sandborn; Maïté Lewin; Joel G Fletcher; Yehuda Chowers; Geert D'Haens; Brian G Feagan; Toshifumi Hibi; Daniel W Hommes; E Jan Irvine; Michael A Kamm; Edward V Loftus; Edouard Louis; Pierre Michetti; Pia Munkholm; Tom Oresland; Julian Panés; Laurent Peyrin-Biroulet; Walter Reinisch; Bruce E Sands; Juergen Schoelmerich; Stefan Schreiber; Herbert Tilg; Simon Travis; Gert van Assche; Maurizio Vecchi; Jean-Yves Mary; Jean-Frédéric Colombel; Marc Lémann
Journal:  Inflamm Bowel Dis       Date:  2010-11-28       Impact factor: 5.325
  9 in total
  2 in total

Review 1.  First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?

Authors:  Laurent Peyrin-Biroulet; Gionata Fiorino; Anthony Buisson; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

2.  Select a suitable treatment strategy for Crohn's disease: step-up or top-down.

Authors:  Qian-Qian Chen; Li Yan; Jun Wan
Journal:  EXCLI J       Date:  2014-02-13       Impact factor: 4.068
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.